Effect of Atorvastatin (10 mg/day) on Glucose Metabolism in Patients With the Metabolic Syndrome

Kahn, 1998, Type 2 diabetes, Cell, 92, 593, 10.1016/S0092-8674(00)81125-3

Chiasson, 2002, Acarbose for prevention of type 2 diabetes mellitus, Lancet, 359, 2072, 10.1016/S0140-6736(02)08905-5

Knowler, 2002, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N Engl J Med, 346, 393, 10.1056/NEJMoa012512

Knowler, 2005, Prevention of type 2 diabetes with troglitazone in the diabetes prevention program, Diabetes, 54, 1150, 10.2337/diabetes.54.4.1150

Tuomilehto, 2001, Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance, N Engl J Med, 334, 1343, 10.1056/NEJM200105033441801

Freeman, 2001, Pravastatin and the development of diabetes mellitus, Circulation, 103, 357, 10.1161/01.CIR.103.3.357

Matthews, 1985, Homeostasis model assessment; insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man, Diabetologia, 412, 10.1007/BF00280883

Bonora, 2000, Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity, Diabetes Care, 23, 57, 10.2337/diacare.23.1.57

Cretti, 2001, Assessment of β-cell function during the oral glucose tolerance test by a minimal model of insulin secretion, Eur J Clin Invest, 31, 405, 10.1046/j.1365-2362.2001.00827.x

Parhofer, 2000, Atorvastatin improves postprandial lipoprotein metabolism in normolipidemic subjects, J Clin Endocrin Metab, 85, 4224

Güclü, 2004, Effects of statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome, Biomed Pharmakother, 58, 614, 10.1016/j.biopha.2004.09.005

Costa, 2003, Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose, Diabetic Med, 20, 743, 10.1046/j.1464-5491.2003.00993.x

Paniagua, 2002, Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes, Diabetes, 51, 2596, 10.2337/diabetes.51.8.2596

Sonmez, 2003, Fluvastatin improves insulin resistance in non-diabetic dyslipidemic patients, Endocrine, 22, 151, 10.1385/ENDO:22:2:151

Watts, 2003, Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome, Diabetes, 52, 803, 10.2337/diabetes.52.3.803

Parhofer, 2003, Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients, J Lipid Res, 44, 1192, 10.1194/jlr.M300011-JLR200

Whitelaw, 2002, Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia, Diabetes Obes Metab, 4, 187, 10.1046/j.1463-1326.2002.00199.x

Kabir, 2005, Molecular evidence supporting the portal theory, Am J Physiol Endocrinol Metab, 288, E454, 10.1152/ajpendo.00203.2004

Dichtl, 2003, HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells, Arterioscler Thromb Vasc Biol, 23, 58, 10.1161/01.ATV.0000043456.48735.20

Pruefer, 2002, Simvastatin inhibits inflammatory properties of Staphylococcus aureus α-toxin, Circulation, 106, 2104, 10.1161/01.CIR.0000034048.38910.91